Loading…

Biology of FasL

FasL (CD95L) is a well-known and well-characterized death-inducing ligand. Spontaneous mutations in FasL and its cognate receptor Fas (CD95) have helped understand the role of these molecules in the disease. Once thought to be mainly involved in the homeostasis of immune system, the territory of Fas...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine & growth factor reviews 2003-06, Vol.14 (3), p.325-335
Main Authors: Lee, Hae-ock, Ferguson, Thomas A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83
cites cdi_FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83
container_end_page 335
container_issue 3
container_start_page 325
container_title Cytokine & growth factor reviews
container_volume 14
creator Lee, Hae-ock
Ferguson, Thomas A.
description FasL (CD95L) is a well-known and well-characterized death-inducing ligand. Spontaneous mutations in FasL and its cognate receptor Fas (CD95) have helped understand the role of these molecules in the disease. Once thought to be mainly involved in the homeostasis of immune system, the territory of FasL regulation has been expanded to angiogenesis and tumor progression. Here, we review what is currently known about the role of FasL in many areas of biology.
doi_str_mv 10.1016/S1359-6101(03)00028-5
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73353678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359610103000285</els_id><sourcerecordid>18797333</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhnNQbK3iL1B6Ej2s5ju7J9FiVSh4UM8hTSYS2TY16Qr996Yf6LGnGWaemRcehM4JviGYyNs3wkRTydJfYXaNMaZ1JQ5Q_2_cQ8c5f5UFZwIfoR6hqlZCNn109hBiGz9Xw-iHY5MnJ-jQmzbD6a4O0Mf48X30XE1en15G95PKcs6XlfeccOqkB0spAJYWT8nUUYV5LTAljnFiqcEeuLXSOTANazxpJJeSKFOzAbrc_l2k-N1BXupZyBba1swhdlkrxgSTaj9IatUUmBVQbEGbYs4JvF6kMDNppQnWa016o0mvfWjM9EaTFuXuYhfQTWfg_q92jgpwtwWg-PgJkHS2AeYWXEhgl9rFsCfiF-j9dfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18797333</pqid></control><display><type>article</type><title>Biology of FasL</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Lee, Hae-ock ; Ferguson, Thomas A.</creator><creatorcontrib>Lee, Hae-ock ; Ferguson, Thomas A.</creatorcontrib><description>FasL (CD95L) is a well-known and well-characterized death-inducing ligand. Spontaneous mutations in FasL and its cognate receptor Fas (CD95) have helped understand the role of these molecules in the disease. Once thought to be mainly involved in the homeostasis of immune system, the territory of FasL regulation has been expanded to angiogenesis and tumor progression. Here, we review what is currently known about the role of FasL in many areas of biology.</description><identifier>ISSN: 1359-6101</identifier><identifier>DOI: 10.1016/S1359-6101(03)00028-5</identifier><identifier>PMID: 12787569</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Angiogenesis ; Animals ; Autoantibodies - biosynthesis ; CTL ; Cytotoxicity, Immunologic ; Fas Ligand Protein ; FasL ; Homeostasis ; Humans ; Immune privilege ; Immune Tolerance ; Membrane Glycoproteins - genetics ; Membrane Glycoproteins - immunology ; Membrane Glycoproteins - physiology ; Mice ; Mice, Mutant Strains ; Models, Immunological ; Mutation ; Neoplasms - immunology ; Neovascularization, Pathologic ; T-Lymphocytes - immunology ; Tumor progression</subject><ispartof>Cytokine &amp; growth factor reviews, 2003-06, Vol.14 (3), p.325-335</ispartof><rights>2003 Elsevier Science Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83</citedby><cites>FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12787569$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Hae-ock</creatorcontrib><creatorcontrib>Ferguson, Thomas A.</creatorcontrib><title>Biology of FasL</title><title>Cytokine &amp; growth factor reviews</title><addtitle>Cytokine Growth Factor Rev</addtitle><description>FasL (CD95L) is a well-known and well-characterized death-inducing ligand. Spontaneous mutations in FasL and its cognate receptor Fas (CD95) have helped understand the role of these molecules in the disease. Once thought to be mainly involved in the homeostasis of immune system, the territory of FasL regulation has been expanded to angiogenesis and tumor progression. Here, we review what is currently known about the role of FasL in many areas of biology.</description><subject>Angiogenesis</subject><subject>Animals</subject><subject>Autoantibodies - biosynthesis</subject><subject>CTL</subject><subject>Cytotoxicity, Immunologic</subject><subject>Fas Ligand Protein</subject><subject>FasL</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Immune privilege</subject><subject>Immune Tolerance</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Membrane Glycoproteins - immunology</subject><subject>Membrane Glycoproteins - physiology</subject><subject>Mice</subject><subject>Mice, Mutant Strains</subject><subject>Models, Immunological</subject><subject>Mutation</subject><subject>Neoplasms - immunology</subject><subject>Neovascularization, Pathologic</subject><subject>T-Lymphocytes - immunology</subject><subject>Tumor progression</subject><issn>1359-6101</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqFkE1LAzEQhnNQbK3iL1B6Ej2s5ju7J9FiVSh4UM8hTSYS2TY16Qr996Yf6LGnGWaemRcehM4JviGYyNs3wkRTydJfYXaNMaZ1JQ5Q_2_cQ8c5f5UFZwIfoR6hqlZCNn109hBiGz9Xw-iHY5MnJ-jQmzbD6a4O0Mf48X30XE1en15G95PKcs6XlfeccOqkB0spAJYWT8nUUYV5LTAljnFiqcEeuLXSOTANazxpJJeSKFOzAbrc_l2k-N1BXupZyBba1swhdlkrxgSTaj9IatUUmBVQbEGbYs4JvF6kMDNppQnWa016o0mvfWjM9EaTFuXuYhfQTWfg_q92jgpwtwWg-PgJkHS2AeYWXEhgl9rFsCfiF-j9dfw</recordid><startdate>20030601</startdate><enddate>20030601</enddate><creator>Lee, Hae-ock</creator><creator>Ferguson, Thomas A.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20030601</creationdate><title>Biology of FasL</title><author>Lee, Hae-ock ; Ferguson, Thomas A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Angiogenesis</topic><topic>Animals</topic><topic>Autoantibodies - biosynthesis</topic><topic>CTL</topic><topic>Cytotoxicity, Immunologic</topic><topic>Fas Ligand Protein</topic><topic>FasL</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Immune privilege</topic><topic>Immune Tolerance</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Membrane Glycoproteins - immunology</topic><topic>Membrane Glycoproteins - physiology</topic><topic>Mice</topic><topic>Mice, Mutant Strains</topic><topic>Models, Immunological</topic><topic>Mutation</topic><topic>Neoplasms - immunology</topic><topic>Neovascularization, Pathologic</topic><topic>T-Lymphocytes - immunology</topic><topic>Tumor progression</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Hae-ock</creatorcontrib><creatorcontrib>Ferguson, Thomas A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cytokine &amp; growth factor reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Hae-ock</au><au>Ferguson, Thomas A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biology of FasL</atitle><jtitle>Cytokine &amp; growth factor reviews</jtitle><addtitle>Cytokine Growth Factor Rev</addtitle><date>2003-06-01</date><risdate>2003</risdate><volume>14</volume><issue>3</issue><spage>325</spage><epage>335</epage><pages>325-335</pages><issn>1359-6101</issn><abstract>FasL (CD95L) is a well-known and well-characterized death-inducing ligand. Spontaneous mutations in FasL and its cognate receptor Fas (CD95) have helped understand the role of these molecules in the disease. Once thought to be mainly involved in the homeostasis of immune system, the territory of FasL regulation has been expanded to angiogenesis and tumor progression. Here, we review what is currently known about the role of FasL in many areas of biology.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>12787569</pmid><doi>10.1016/S1359-6101(03)00028-5</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1359-6101
ispartof Cytokine & growth factor reviews, 2003-06, Vol.14 (3), p.325-335
issn 1359-6101
language eng
recordid cdi_proquest_miscellaneous_73353678
source ScienceDirect Freedom Collection 2022-2024
subjects Angiogenesis
Animals
Autoantibodies - biosynthesis
CTL
Cytotoxicity, Immunologic
Fas Ligand Protein
FasL
Homeostasis
Humans
Immune privilege
Immune Tolerance
Membrane Glycoproteins - genetics
Membrane Glycoproteins - immunology
Membrane Glycoproteins - physiology
Mice
Mice, Mutant Strains
Models, Immunological
Mutation
Neoplasms - immunology
Neovascularization, Pathologic
T-Lymphocytes - immunology
Tumor progression
title Biology of FasL
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T16%3A51%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biology%20of%20FasL&rft.jtitle=Cytokine%20&%20growth%20factor%20reviews&rft.au=Lee,%20Hae-ock&rft.date=2003-06-01&rft.volume=14&rft.issue=3&rft.spage=325&rft.epage=335&rft.pages=325-335&rft.issn=1359-6101&rft_id=info:doi/10.1016/S1359-6101(03)00028-5&rft_dat=%3Cproquest_cross%3E18797333%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=18797333&rft_id=info:pmid/12787569&rfr_iscdi=true